CAS: 1309357-15-0; Sodium 5-((3-Chlorophenyl)Amino)Benzo[c][2,6]Naphthyridine-8-Carboxylate

主要参考文献

1: Silva-Pavez E, Villar P, Trigo C, Caamaño E, Niechi I, Pérez P, Muñoz JP, Aguayo F, Burzio VA, Varas-Godoy M, Castro AF, Colombo MI, Tapia JC. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells. Cell Death Dis. 2019 Jan 25;10(2):73. doi: 10.1038/s41419-019-1306-x.
2: Zhong B, Campagne O, Salloum R, Purzner T, Stewart CF. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122254. doi: 10.1016/j.jchromb.2020.122254. Epub 2020 Jun 23.
3: Wang H, Lv Q, Xu Y, Cai Z, Zheng J, Cheng X, Dai Y, Jänne PA, Ambrogio C, Köhler J. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. EBioMedicine. 2019 Nov;49:106-117. doi: 10.1016/j.ebiom.2019.10.012. Epub 2019 Oct 23.